Search results for "Hcv treatment"

showing 5 items of 5 documents

Viral resistance in HCV infection.

2018

The introduction of new multi-genotypic direct acting antivirals (DAA) in clinical practice has revolutionized HCV treatment, permitting the achievement of >95% rates of sustained virological response in many patients. However, virological failures can occur particularly if the treatments are sub optimal and/or with too short duration. Failure is often associated with development of resistance. The wide genetic variability in terms of different genotypes and subtypes, together with the natural presence and/or easy development of resistance during treatment, are intrinsic characteristics of HCV that may affect the treatment outcome and the chances of achieving a virological cure. This review…

0301 basic medicineGenotypeTreatment outcomeDrug ResistanceDrug resistanceHepacivirusBiologyViral resistanceAntiviral AgentsVirological response03 medical and health sciences0302 clinical medicinePharmacotherapyDrug TherapyDrug Resistance Multiple ViralVirologyRibavirinmedicineHumansGenetic variabilityViralTreatment FailureChronicAntiviral Agents; Drug Therapy Combination; Genetic Variation; Genotype; Hepacivirus; Hepatitis C Chronic; Humans; Interferons; Ribavirin; Treatment Failure; Drug Resistance Multiple ViralGenetic VariationHepatitis CHepatitis C Chronicmedicine.diseaseSettore MED/07 - Microbiologia e Microbiologia ClinicaHepatitis C030104 developmental biologyHCVImmunologyCombinationHcv treatment030211 gastroenterology & hepatologyDrug Therapy CombinationInterferonsMultipleCurrent opinion in virology
researchProduct

Current practice of hepatitis C treatment in Southern Italy.

2010

Abstract Background Only a small proportion of subjects referring to hospitals for hepatitis C virus (HCV) positivity receives antiviral therapy. Aim To evaluate the rate of antiviral treatment and the causes for no treatment in HCV-RNA positive subjects seen in hospital settings. Patients and methods A prospective study enrolling over a 6-month period (February–July 2009) all consecutive anti-HCV positive subjects initially referred (naive patients) to 12 liver units in Southern Italy for HCV treatment. Results Out of 608 subjects evaluated, 74 (12.2%) had no detectable HCV-RNA in the serum and thus were excluded. Of the remaining 534 HCV-RNA positive subjects, 357 (66.9%) were not treated…

AdultMalemedicine.medical_specialtyMultivariate analysisHepatitis C virusAlcohol abuseHepacivirusInterferon alpha-2medicine.disease_causeAntiviral AgentsPolyethylene GlycolsTreatment RefusalSex FactorsInternal medicineRibavirinHumansMedicineProspective StudiesProspective cohort studyAgedHepatologybusiness.industryGastroenterologyAntiviral therapyInterferon-alphaAlanine TransaminaseHepatitis CHepatitis C AntibodiesMiddle Agedmedicine.diseaseHepatitis CRecombinant ProteinsAlcoholismTreatment OutcomeItalyCurrent practiceImmunologyHCVHcv treatmentEducational StatusRNA ViralFemalebusiness
researchProduct

New therapeutic prospects in HCV treatment.

2008

Microbiology (medical)business.industryHepacivirusBioinformaticsMicrobiologyAntiviral AgentsHepatitis CInfectious DiseasesText miningVirologyDrug Resistance ViralHcv treatmentMedicineHumansbusinessExpert review of anti-infective therapy
researchProduct

Health policy model: long-term predictive results associated with the management of hepatitis C virus-induced diseases in Italy

2014

Francesco Saverio Mennini,1,2 Andrea Marcellusi,1,3 Massimo Andreoni,4 Antonio Gasbarrini,5 Salvatore Salomone,6 Antonio Craxì71Centre for Economic and International Studies (CEIS) – Economic Evaluation and HTA (EEHTA) Faculty of Economics, University of Rome Tor Vergata, Rome, Italy; 2Institute of Leadership and Management in Health, Kingston University, London, UK; 3Department of Demography, University of Rome La Sapienza, Rome, Italy; 4Department of Public Health and Cell Biology, School of Medicine, University of Rome Tor Vergata, Rome, Italy; 5Gastroenterology Division, Catholic University of the Sacred Heart of Rome, School of Medicine, Rome, Italy; 6Department of…

Operations researchHepatitis C virusSettore MED/12 - GASTROENTEROLOGIAEconomics Econometrics and Finance (miscellaneous)forecastcost of illnessmacromolecular substancesmedicine.disease_causeChronic hepatitisEnvironmental healthCost of illnessMedicineHealth policyOriginal Researchlcsh:R5-920business.industryHealth Policylcsh:RM1-950Health services researchvirus diseasesSettore SECS-S/04 - Demografianew HCV treatmentClinicoEconomics and Outcomes Researchlcsh:Therapeutics. Pharmacologychronic hepatitishepatitis Cbusinesslcsh:Medicine (General)ClinicoEconomics and Outcomes Research
researchProduct

Current epidemiology of HCV in Sicily: the RESIST-HCV model

2019

Background: Real-world data to guide hepatitis C virus (HCV)- related public health initiatives and linkage to care of patients are lacking in our region. Aims: To describe the epidemiological features of a large cohort of patients with chronic HCV infection from Sicily included in a regional network aimed at DAA treatment (RESIST-HCV). Methods: Demographic and clinical data were recorded on a web-based platform before starting treatment with DAAs. Gender, year of birth, HCV genotype, co-infections, stages of liver disease and co-morbidities were analyzed. Chi-square with Yates correc- tion was appliedto assess the differences between cohorts. Results: Overall, 15,270 patients were register…

medicine.medical_specialtyHepatologyResistbusiness.industryEpidemiologyGastroenterologymedicineHCV treatmentCurrent (fluid)clinical surveillancebusinessIntensive care medicineepidemiology of HCVDigestive and Liver Disease
researchProduct